Browsing by Author "Ansotegui, Ignacio"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Item
    Open Access
    Climate Change, Migration, and Allergic Respiratory Diseases: An Update for the Allergist
    (BioMed Central Ltd, 2011) D'Amato, Gennaro; Rottem, Menachem; Dahl, Ronald; Blaiss, Michael; Ridolo, Erminia; Cecchi, Lorenzo; Rosario, Nelson; Motala, Cassim; Ansotegui, Ignacio; Annesi-Maesano, Isabella; the WAO Special Committee on Climate Change and Allergy
    Local climate changes can impact on a number of factors, including air pollution, that have been shown to influence both the development and attacks of allergic respiratory diseases, and they thus represent an important consideration for the allergist. Migration involves exposure to a new set of pollutants and allergens and changes in housing conditions, diet and accessibility to medical services, all of which are likely to affect migrants' health. This review provides an update on climate change, migration, and allergy and discusses factors for consideration when making recommendations for local allergy service provision, and for assessing an individual patient's environmental exposures.
  • Thumbnail Image
    Item
    Open Access
    Diagnosis and treatment of urticaria and angioedema: a worldwide perspective
    (BioMed Central Ltd, 2012) Sánchez-Borges, Mario; Asero, Riccardo; Ansotegui, Ignacio; Baiardini, Ilaria; Bernstein, Jonathan; Canonica, G Walter; Gower, Richard; Kahn, David; Kaplan, Allen; Katelaris, Connie; Maurer, Marcus; Park, Hae; Potter, Paul; Saini, Sarbjit; Tassinari
    Urticaria and angioedema are common clinical conditions representing a major concern for physicians and patients alike. The World Allergy Organization (WAO), recognizing the importance of these diseases, has contributed to previous guidelines for the diagnosis and management of urticaria. The Scientific and Clinical Issues Council of WAO proposed the development of this global Position Paper to further enhance the clinical management of these disorders through the participation of renowned experts from all WAO regions of the world. Sections on definition and classification, prevalence, etiology and pathogenesis, diagnosis, treatment, and prognosis are based on the best scientific evidence presently available. Additional sections devoted to urticaria and angioedema in children and pregnant women, quality of life and patient-reported outcomes, and physical urticarias have been incorporated into this document. It is expected that this article will supplement recent international guidelines with the contribution of an expert panel designated by the WAO, increasing awareness of the importance of urticaria and angioedema in medical practice and will become a useful source of information for optimum patient management worldwide.
  • Thumbnail Image
    Item
    Open Access
    The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update
    (BioMed Central, 2018-02-27) Maurer, Marcus; Magerl, Markus; Ansotegui, Ignacio; Aygören-Pürsün, Emel; Betschel, Stephen; Bork, Konrad; Bowen, Tom; Boysen, Henrik B; Farkas, Henriette; Grumach, Anete S; Hide, Michihiro; Katelaris, Constance; Lockey, Richard; Longhurst, Hilary; Lumry, William R.; Martinez-Saguer, Inmaculada; Moldovan, Dumitru; Nast, Alexander; Pawankar, Ruby; Potter, Paul; Riedl, Marc; Ritchie, Bruce; Rosenwasser, Lanny; Sánchez-Borges, Mario; Zhi, Yuxiang; Zuraw, Bruce; Craig, Timothy
    Hereditary Angioedema (HAE) is a rare and disabling disease. Early diagnosis and appropriate therapy are essential. This update and revision of the global guideline for HAE provides up-to-date consensus recommendations for the management of HAE. In the development of this update and revision of the guideline, an international expert panel reviewed the existing evidence and developed 20 recommendations that were discussed, finalized and consented during the guideline consensus conference in June 2016 in Vienna. The final version of this update and revision of the guideline incorporates the contributions of a board of expert reviewers and the endorsing societies. The goal of this guideline update and revision is to provide clinicians and their patients with guidance that will assist them in making rational decisions in the management of HAE with deficient C1-inhibitor (type 1) and HAE with dysfunctional C1-inhibitor (type 2). The key clinical questions covered by these recommendations are: 1) How should HAE-1/2 be defined and classified?, 2) How should HAE-1/2 be diagnosed?, 3) Should HAE-1/2 patients receive prophylactic and/or on-demand treatment and what treatment options should be used?, 4) Should HAE-1/2 management be different for special HAE-1/2 patient groups such as pregnant/lactating women or children?, and 5) Should HAE-1/2 management incorporate self-administration of therapies and patient support measures? This article is co-published with permission in Allergy and the World Allergy Organization Journal.